Eva P Szymanski1, Janice M Leung1, Cedar J Fowler1, Carissa Haney1, Amy P Hsu1, Fei Chen2, Priya Duggal2, Andrew J Oler3, Ryan McCormack4, Eckhard Podack4, Rebecca A Drummond1, Michail S Lionakis1, Sarah K Browne1, D Rebecca Prevots1, Michael Knowles5, Gary Cutting6, Xinyue Liu7, Scott E Devine7,8, Claire M Fraser7,8, Hervé Tettelin7,9, Kenneth N Olivier10, Steven M Holland1. 1. 1 Laboratory of Clinical Infectious Diseases. 2. 2 Department of Epidemiology, Bloomberg School of Public Health, and. 3. 3 Bioinformatics and Computational Biosciences Branch, Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, and. 4. 4 Department of Microbiology and Immunology, School of Medicine, University of Miami, Miami, Florida. 5. 5 Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; and. 6. 6 McKusick-Nathans Institute of Genetic Medicine, School of Medicine, The Johns Hopkins University, Baltimore, Maryland. 7. 7 Institute for Genome Sciences. 8. 8 Department of Medicine, and. 9. 9 Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, Maryland. 10. 10 Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Abstract
RATIONALE: The clinical features of patients infected with pulmonary nontuberculous mycobacteria (PNTM) are well described, but the genetic components of infection susceptibility are not. OBJECTIVES: To examine genetic variants in patients with PNTM, their unaffected family members, and a control group. METHODS: Whole-exome sequencing was done on 69 white patients with PNTM and 18 of their white unaffected family members. We performed a candidate gene analysis using immune, cystic fibrosis transmembrance conductance regulator (CFTR), cilia, and connective tissue gene sets. The numbers of patients, family members, and control subjects with variants in each category were compared, as was the average number of variants per person. MEASUREMENTS AND MAIN RESULTS: A significantly higher number of patients with PNTM than the other subjects had low-frequency, protein-affecting variants in immune, CFTR, cilia, and connective tissue categories (35, 26, 90, and 90%, respectively). Patients with PNTM also had significantly more cilia and connective tissue variants per person than did control subjects (2.47 and 2.55 compared with 1.38 and 1.40, respectively; P = 1.4 × 10(-6) and P = 2.7 × 10(-8), respectively). Patients with PNTM had an average of 5.26 variants across all categories (1.98 in control subjects; P = 2.8 × 10(-17)), and they were more likely than control subjects to have variants in multiple categories. We observed similar results for family members without PNTM infection, with the exception of the immune category. CONCLUSIONS: Patients with PNTM have more low-frequency, protein-affecting variants in immune, CFTR, cilia, and connective tissue genes than their unaffected family members and control subjects. We propose that PNTM infection is a multigenic disease in which combinations of variants across gene categories, plus environmental exposures, increase susceptibility to the infection.
RATIONALE: The clinical features of patientsinfected with pulmonary nontuberculous mycobacteria (PNTM) are well described, but the genetic components of infection susceptibility are not. OBJECTIVES: To examine genetic variants in patients with PNTM, their unaffected family members, and a control group. METHODS: Whole-exome sequencing was done on 69 white patients with PNTM and 18 of their white unaffected family members. We performed a candidate gene analysis using immune, cystic fibrosis transmembrance conductance regulator (CFTR), cilia, and connective tissue gene sets. The numbers of patients, family members, and control subjects with variants in each category were compared, as was the average number of variants per person. MEASUREMENTS AND MAIN RESULTS: A significantly higher number of patients with PNTM than the other subjects had low-frequency, protein-affecting variants in immune, CFTR, cilia, and connective tissue categories (35, 26, 90, and 90%, respectively). Patients with PNTM also had significantly more cilia and connective tissue variants per person than did control subjects (2.47 and 2.55 compared with 1.38 and 1.40, respectively; P = 1.4 × 10(-6) and P = 2.7 × 10(-8), respectively). Patients with PNTM had an average of 5.26 variants across all categories (1.98 in control subjects; P = 2.8 × 10(-17)), and they were more likely than control subjects to have variants in multiple categories. We observed similar results for family members without PNTM infection, with the exception of the immune category. CONCLUSIONS:Patients with PNTM have more low-frequency, protein-affecting variants in immune, CFTR, cilia, and connective tissue genes than their unaffected family members and control subjects. We propose that PNTM infection is a multigenic disease in which combinations of variants across gene categories, plus environmental exposures, increase susceptibility to the infection.
Entities:
Keywords:
bronchiectasis; cilia; genetics; immune system diseases; nontuberculous mycobacteria
Authors: Janice M Leung; Cedar Fowler; Caroline Smith; Jennifer Adjemian; Cathleen Frein; Reginald J Claypool; Steven M Holland; Rebecca D Prevots; Kenneth Olivier Journal: Am J Respir Crit Care Med Date: 2013-12-01 Impact factor: 21.405
Authors: Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly Journal: Nat Genet Date: 2011-04-10 Impact factor: 38.330
Authors: Fei Chen; Eva P Szymanski; Kenneth N Olivier; Xinyue Liu; Hervé Tettelin; Steven M Holland; Priya Duggal Journal: Am J Respir Crit Care Med Date: 2017-12-15 Impact factor: 21.405
Authors: David E Griffith; Jennifer Adjemian; Barbara A Brown-Elliott; D Rebecca Prevots; Julie V Philley; Kenneth N Olivier; Richard J Wallace Journal: Am J Respir Crit Care Med Date: 2015-11-15 Impact factor: 21.405
Authors: Eva P Szymanski; Janice M Leung; Cedar J Fowler; Carissa Haney; Amy P Hsu; Fei Chen; Priya Duggal; Andrew J Oler; Ryan McCormack; Eckhard Podack; Rebecca A Drummond; Michail S Lionakis; Sarah K Browne; D Rebecca Prevots; Michael Knowles; Gary Cutting; Xinyue Liu; Scott E Devine; Claire M Fraser; Hervé Tettelin; Kenneth N Olivier; Steven M Holland Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Ryan M McCormack; Eva P Szymanski; Amy P Hsu; Elena Perez; Kenneth N Olivier; Eva Fisher; E Brook Goodhew; Eckhard R Podack; Steven M Holland Journal: JCI Insight Date: 2017-04-20
Authors: M Leigh Anne Daniels; Katherine R Birchard; Jared R Lowe; Michael V Patrone; Peadar G Noone; Michael R Knowles Journal: Ann Am Thorac Soc Date: 2016-10
Authors: Emily Henkle; Timothy Aksamit; Alan Barker; Charles L Daley; David Griffith; Philip Leitman; Amy Leitman; Elisha Malanga; Theodore K Marras; Kenneth N Olivier; D Rebecca Prevots; Delia Prieto; Alexandra L Quittner; William Skach; John W Walsh; Kevin L Winthrop Journal: Ann Am Thorac Soc Date: 2016-09